Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT)
He began his medical career at Middlesex Hospital, UCL, where he was also a Medical Research Council clinical fellow
Key highlights Tirzepatide is a once-weekly injectable medication that acts as a dual agonist of GLP-1 & GIP receptors, while orforglipron is a daily oral GLP-1 receptor agonist
The mechanism is not yet fully understood, but it may relate to the glucagon receptor activation or the broader metabolic changes that the triple agonist produces
Serious side effects are rare but may include elevated liver enzymes or gallbladder issues
This widespread use of these popular weight loss drugs, both for approved diabetes treatment and off-label weight loss, has now resulted in thousands of patients reporting severe gastrointestinal injuries and vision loss, conditions that many allege were not adequately disclosed on warning labels when they began treatment
